Suppr超能文献

低剂量分次全身照射(TBI)对接受来自无关供体的HLA匹配异基因骨髓移植(UD-BMT)的白血病患者的预后有不利影响。

Low-dose fractionated total body irradiation (TBI) adversely affects prognosis of patients with leukemia receiving an HLA-matched allogeneic bone marrow transplant from an unrelated donor (UD-BMT).

作者信息

Corvò R, Lamparelli T, Bruno B, Barra S, Van Lint M T, Vitale V, Bacigalupo A

机构信息

UO Oncologia Radioterapica, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy.

出版信息

Bone Marrow Transplant. 2002 Dec;30(11):717-23. doi: 10.1038/sj.bmt.1703701.

Abstract

The optimal total body irradiation (TBI) regimen for unrelated donor bone marrow transplant (UD-BMT) is unknown. In the present study we analyze the outcomes of two different TBI regimens used in our center for patients with leukemia undergoing an UD-BMT. Between January 1994 and August 2001, 99 consecutive UD-BMT patients entered this comparative study. The conditioning regimen consisted of cyclophosphamide, 120 mg/kg followed by TBI on days -3, -2 and -1. Forty-six patients received TBI 12 Gy (2 Gy, twice a day) in six fractions (HF-TBI) and 53 patients received TBI 9.90 Gy (3.30 Gy per day) fractionated over 3 days (F-TBI). End-points were transplanted-related mortality (TRM), leukemia relapse rate (LRR) and overall survival (OS). At median follow-up of 22 months (58 months for HF-TBI and 17 for F-TBI, respectively), 60 patients were alive (32 in HF-TBI sub-group and 28 in F-TBI one). The actuarial 5-year TRM was 31% for HF-TBI and 41% for F-TBI (P = 0.1), whereas the 5-year LRR was 13% for HF-TBI and 31% for F-TBI (P = 0.04). The actuarial 5-year OS was 68% for patients treated with HF-TBI and 51% for those treated with F-TBI (P = 0.02). At multivariate analysis F-TBI schedule emerged as an adverse predictor for OS (P = 0.04) and LRR (P = 0.03). These data indicate that a lower total dose of TBI appears significantly less effective in leukemia eradication and associated with worse overall survival when compared with a higher dose of radiation.

摘要

无关供体骨髓移植(UD - BMT)的最佳全身照射(TBI)方案尚不清楚。在本研究中,我们分析了本中心用于接受UD - BMT的白血病患者的两种不同TBI方案的结果。1994年1月至2001年8月,99例连续的UD - BMT患者进入了这项对比研究。预处理方案包括环磷酰胺,120mg/kg,然后在第 - 3、 - 2和 - 1天进行TBI。46例患者接受12Gy的TBI(2Gy,每天两次),分六次照射(HF - TBI),53例患者接受9.90Gy的TBI(每天3.30Gy),分3天照射(F - TBI)。终点指标为移植相关死亡率(TRM)、白血病复发率(LRR)和总生存率(OS)。中位随访22个月(HF - TBI组为58个月,F - TBI组为17个月)时,60例患者存活(HF - TBI亚组32例,F - TBI组28例)。HF - TBI组的5年精算TRM为31%,F - TBI组为41%(P = 0.1),而HF - TBI组的5年LRR为13%,F - TBI组为31%(P = 0.04)。接受HF - TBI治疗的患者的5年精算OS为68%,接受F - TBI治疗的患者为51%(P = 0.02)。多因素分析显示,F - TBI方案是OS(P = 0.04)和LRR(P = 0.03)的不良预测因素。这些数据表明,与较高剂量的辐射相比,如果TBI的总剂量较低,在根除白血病方面似乎明显效果较差,并且与较差的总生存率相关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验